Leprosy hijacks our immune system, turning an important repair mechanism into one that causes potentially irreparable damage to our nerve cells, according to new research that uses zebrafish to study the disease. As such, the disease may share common characteristics with conditions such as multiple sclerosis.
A protein activated by vitamin D could be involved in repairing damage to myelin in people with multiple sclerosis (MS), according to new research from the University of Cambridge. The study, published today in the Journal of Cell Biology, offers significant evidence that vitamin D could be a possible treatment for MS in the future.
Nerve cells damaged in diseases such as multiple sclerosis (MS), ‘talk’ to stem cells in the same way that they communicate with other nerve cells, calling out for ‘first aid’, according to new research from the University of Cambridge.
Like conducting an errant orchestra to play together, researchers are guiding processes that go awry in multiple sclerosis to repair themselves.
A new drug based on decades of research at the University of Cambridge has today been approved by the National Institute for Health and Care Excellence (NICE) for use in people with relapsing-remitting multiple sclerosis. Clinical trials have shown that Alemtuzumab, marketed under the name Lemtrada, reduces disease activity, limits the accumulation of further disability over time and may even allow some existing damage to recover.
Brings to 110 known risk factors and provides important insight into disease mechanism.
Approval concludes nearly 40-year epic journey from fundamental research to discovery of an effective treatment for active relapsing multiple sclerosis
Multiple sclerosis treatments that repair damage to the brain could be developed thanks to new research.
Cambridge researchers developing new therapies as part of a collaborative programme with industry.
Alemtuzumab, a drug previously used to treat a type of leukaemia, shown to help people with early multiple sclerosis who relapsed on previous drugs as well as patients who had not yet been treated.